Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
about
Bone Tumor Environment as a Potential Therapeutic Target in Ewing SarcomaZoledronic acid: clinical utility and patient considerations in osteoporosis and low bone massTreatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.Sterol-regulatory-element-binding protein 2 and nuclear factor Y control human farnesyl diphosphate synthase expression and affect cell proliferation in hepatoblastoma cells.
P2860
Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
@en
Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
@nl
type
label
Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
@en
Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
@nl
prefLabel
Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
@en
Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
@nl
P2860
P1476
Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
@en
P2093
Adam M Brufsky
P2860
P304
P356
10.1517/14656566.9.6.1013
P407
P577
2008-04-01T00:00:00Z